Table:

Base-case/ scenario	Incremental costs	Incremental QALYs	ICUR
Base-case	–$5,064	0.17	Dominant
#1 15% sorafenib price reduction	–$1,310	0.17	Dominant
#2 Adjustment for post-progression therapies and regorafenib only post-progression	–$9,391	0.22	Dominant
#3 Scenarios 1 & 2 combined	–$5,141	0.22	Dominant

Abbreviations: ICUR, incremental cost-utility ration; QALYs, quality-adjusted life years.